
Duke University researchers have created an AI program called Raygun that shrinks proteins by 10–15% while preserving their function, a breakthrough published in Nature.
The tool identifies which amino acids are critical by analyzing evolutionary patterns, making it potentially useful for medical applications like gene therapy and biological imaging, where smaller proteins would fit more easily into delivery vehicles or interfere less with tagging.
What happened
Researchers at Duke University have developed an AI program called Raygun that can suggest cuts to a protein's amino acid sequence, reducing overall size without losing function. The tool shrank fluorescent proteins EGFP and mCherry by 10–15%, and the resulting proteins still glowed under excitation.
Why it matters
Smaller proteins could reduce interference when tagging biological processes, and shrinking sequences may help gene therapy by fitting into the limited capacity of delivery vehicles like adeno-associated viruses. The approach works by learning from evolutionary patterns in protein sequences to identify critical pieces, rather than testing mutations one at a time.
What to watch
The tool can also expand proteins, which researchers are still developing—a capability that could help add new domains to existing proteins. Raygun is not positioned as a replacement for de novo protein design (creating proteins from scratch) but rather as a complement; both techniques could be used together.
Duke University researchers, led by computational biologist Rohit Singh in collaboration with colleague Scott Soderling, have developed an AI-based program called Raygun that can strategically reduce a protein's size without compromising its function. The tool works by analyzing evolutionary patterns embedded in protein sequences to identify which amino acids are truly critical. As Singh explains, "This is an approach that essentially reasons from evolutionary patterns in protein sequences to figure out what the critical pieces are. You can ask for much more extensive substitutions than you would typically have by point-by-point mutations."
In initial tests, Raygun shrank two widely used fluorescent proteins—EGFP and mCherry—by 10–15% while preserving their luminescent properties; the resulting proteins still glowed when exposed to excitation. The findings were published in Nature (2026, DOI: 10.1038/s41586-026-10842-8).
The applications are significant for two major areas of biomedicine. In imaging, miniaturized fluorescent protein tags could reduce their intrusiveness when marking biological processes and tissues, lowering the risk that the tag itself distorts the system being observed. In gene therapy, one of the core challenges is the limited cargo capacity of delivery vehicles like adeno-associated viruses; shrinking therapeutic proteins could open up new treatment possibilities. Singh notes that the two leading strategies in protein engineering—de novo design (creating proteins from scratch) and Raygun's approach (optimizing existing sequences)—are not competitors. Instead, they complement each other: "De novo design is about creating something in an entirely new part of the protein space. Raygun is about exploring the space around it more effectively. So you could actually make a de novo design and then still apply Raygun on top of it to then explore the space around that specific novel design."
Looking forward, the team is developing an additional capability: the ability to expand proteins as well as shrink them. While counterintuitive, expanding a protein could be valuable if researchers want to integrate a new functional domain into an existing protein scaffold. This bidirectional flexibility suggests Raygun may become a versatile tool for protein optimization across a range of biotechnology applications.
Raygun represents a distinct strategy in protein engineering: rather than designing proteins entirely from scratch, it works within the boundaries of known protein sequences, using AI to identify which amino acids are truly essential and which can be removed or substituted. This approach, led by computational biologist Rohit Singh at Duke University, harnesses evolutionary patterns embedded in protein sequences to guide the search for critical components—a method that allows for more extensive modifications than traditional point-by-point mutation testing would suggest.
The practical implications align with real bottlenecks in biotechnology. Gene therapy faces a fundamental constraint: viral delivery vehicles have limited carrying capacity, and any reduction in the size of a therapeutic protein could expand the range of candidates. Similarly, fluorescent protein tags, while invaluable for imaging biological processes, can sometimes alter the very systems they are meant to observe; miniaturizing them could mitigate this interference. Singh's team views Raygun not as a replacement for de novo design but as a complementary tool that can operate on top of newly engineered proteins, effectively allowing researchers to refine and optimize novel designs further.
AI-summarized, only the topics you pick — one digest a day via Email, Slack, or Discord.
Free · takes 30 seconds · unsubscribe anytime
Ask AI anything about this article. Q&As are published on this page for other readers too.
Novo Nordisk has entered a strategic partnership with Amazon Web Services (AWS) to accelerate drug discovery u…

Novo Nordisk and Amazon have signed a partnership agreement focused on AI-driven drug discovery and announced…

Google and Cleveland Clinic announced a partnership to develop AI-powered robotic systems designed to improve…

Graph neural networks are being deployed to detect pharmaceutical counterfeiting and fraud by revealing hidden…

BGI-Research, a Chinese research institute, has released OneGenome, an open-source AI system that interprets D…

Kinney Drugs is pulling back its AI assistant Burt, which the Vermont pharmacy chain introduced in May to hand…

The AI news that matters, in one minute each morning.
Sign up free